Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Varenicline for Light Smokers (ChanLight)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01639560
Recruitment Status : Completed
First Posted : July 12, 2012
Results First Posted : October 13, 2016
Last Update Posted : February 22, 2018
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Jon Ebbert, Mayo Clinic

Brief Summary:
The purpose of this study is to determine if varenicline is effective in treating tobacco dependence in adults who smoke 5-10 cigarettes per day.

Condition or disease Intervention/treatment Phase
Smoking Drug: Varenicline Drug: Placebo Phase 4

Detailed Description:
Nearly 50% of U.S. cigarette smokers smoke ≤ 10 cigarettes per day (CPD) and are considered "light smokers." Most light smokers will either maintain a chronic light smoking habit or increase their level of smoking during their lifetime. Importantly, light smokers are at risk for adverse health consequences and increased all-cause mortality. While multiple factors such as reinforcement behavior, diminished autonomy, economic constraints and tobacco control policies influence light smoking, nicotine dependence appears particularly important in 5 to 10 CPD smokers. Despite the high prevalence of light smoking and its increased healthcare burden, few studies have evaluated the efficacy of pharmacotherapy for this group of smokers. Varenicline, which targets symptoms of nicotine dependence, has been shown to increase smoking abstinence rates in moderate to heavy smokers (≥ 10 cigarettes per day). However, varenicline has not been evaluated in subjects who smoke < 10 CPD. In the current proposal we will investigate the efficacy of varenicline for smoking cessation in 5 to 10 CPD light smokers who wish to quit. This study will be conducted as a double-blind, placebo-controlled, randomized clinical trial at the Mayo Clinic, enrolling 224 eligible participants who smoke 5 to 10 CPD. Participants will receive behavior therapy and either varenicline or placebo for 12 weeks with follow up through 26 weeks. We will determine if varenicline increases smoking abstinence in light smokers at end-of-treatment and 26 weeks as compared to placebo.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 93 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Varenicline for Light Smokers
Study Start Date : January 2013
Actual Primary Completion Date : December 2015
Actual Study Completion Date : June 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Smoking

Arm Intervention/treatment
Active Comparator: Varenicline
1 mg of varenicline twice per day for 12 weeks.
Drug: Varenicline
1 mg of varenicline twice per day for 12 weeks and brief behavioral counseling
Other Name: chantix

Placebo Comparator: placebo
1 placebo tablet twice a day for 12 weeks
Drug: Placebo
1 placebo tablet twice per day for 12 weeks and brief behavioral counseling
Other Name: sugar pill




Primary Outcome Measures :
  1. Point Prevalence Smoking Outcome at 12 Weeks (End of Treatment) [ Time Frame: 12 weeks ]
    To determine the efficacy of 12 weeks of varenicline therapy in achieving increased smoking abstinence rates in light smokers. Point prevalence is defined as no smoking in the past 7 days.

  2. Prolonged Smoking Outcome at 12 Weeks (End of Treatment) [ Time Frame: 12 weeks ]
    To determine the efficacy of 12 weeks of varenicline therapy in achieving increased smoking abstinence rates in light smokers. Prolonged abstinence is defined as no smoking since 2 weeks after the target quit date.


Secondary Outcome Measures :
  1. Point Prevalence Smoking Outcome at 24 Weeks (End of Study) [ Time Frame: 24 weeks ]
    To determine the efficacy of 12 weeks of varenicline therapy in achieving increased smoking abstinence rates at 6 months in light smokers. Point prevalence is defined as no smoking in the past 7 days.

  2. Prolonged Smoking Outcome at 24 Weeks (End of Study) [ Time Frame: 24 weeks ]
    To determine the efficacy of 12 weeks of varenicline therapy in achieving increased smoking abstinence rates at 6 months in light smokers. Prolonged abstinence is defined as no smoking since 2 weeks after the target quit date.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subjects must be ≥ 18 years of age;
  2. smokes 5 to 10 CPD for at least 6 months;
  3. express interest in quitting smoking;
  4. indicate ability to complete all study visits; and
  5. provide written informed consent to participate in the study.
  6. Subject is a female subject of non-childbearing potential or a female subject of childbearing potential - who is using contraceptives and has a negative pregnancy test result;
  7. Subject is in good health as determined by the investigator;
  8. Subject has the ability to participate fully in all aspects of the study and keep scheduled appointments.

Exclusion Criteria:

  1. An active medical condition such as unstable angina, myocardial infarction, or coronary angioplasty within the past 3 months or an untreated cardiac dysrhythmia;
  2. History of renal failure;
  3. Cancer [excluding non-melanoma skin cancer] not in remission;
  4. Psychosis or bipolar disorder;
  5. Current unstable or untreated moderate or severe depression as assessed by the CES-D;
  6. have, as defined by the C-SSRS (Columbia-Suicide Severity Rating Scale), current non-specific suicidal thoughts, or have a lifetime history of a suicidal attempt (defined as "potentially self-injurious act committed with at least some wish to die, as a result of act.");
  7. Substance dependence other than nicotine, defined as:

    a. Patient has a recent history (past month) of heavy alcohol consumption as defined by NIAAA: i. Men: More than 4 drinks on any day or 14 per week ii. Women: More than 3 drinks on any day or 7 per week. b. Use of cocaine, heroin, club drugs (i.e., MDMA/"ecstasy"), methamphetamine, or hallucinogens (e.g., LSD) at any time during the past month.

    c. Use of marijuana on a weekly basis for the past month

  8. An allergy to varenicline;
  9. Current use of a behavioral or pharmacologic tobacco dependence treatment and unwilling or unable to discontinue use;
  10. Another member of their household already participating in this study; and
  11. Current treatment with another investigational drug (within 30 days of study entry).
  12. Has an unstable medical condition;
  13. Subject has untreated hypertension or baseline systolic blood pressure > 180 or diastolic > 100;
  14. Women of child-bearing potential, or who are pregnant, lactating or likely to become pregnant during the trial and are unwilling to use an acceptable form of contraception during the medication phase will also be excluded. All female subjects of childbearing potential must have a negative pregnancy test and must agree to use approved contraception during participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01639560


Locations
Layout table for location information
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Pfizer
Investigators
Layout table for investigator information
Principal Investigator: Jon O. Ebbert, MD Mayo Clinic
Principal Investigator: Ivana T. Croghan, PhD Mayo Clinic

Publications of Results:
Layout table for additonal information
Responsible Party: Jon Ebbert, Principal Investigator, Mayo Clinic
ClinicalTrials.gov Identifier: NCT01639560     History of Changes
Other Study ID Numbers: 12-005652
WS2293926 ( Other Grant/Funding Number: Pfizer Inc )
First Posted: July 12, 2012    Key Record Dates
Results First Posted: October 13, 2016
Last Update Posted: February 22, 2018
Last Verified: January 2018

Keywords provided by Jon Ebbert, Mayo Clinic:
smoking
tobacco dependence
nicotine dependence

Additional relevant MeSH terms:
Layout table for MeSH terms
Varenicline
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs